KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Assets Average (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Assets Average data on record, last reported at $1.4 billion in Q4 2025.

  • For Q4 2025, Assets Average rose 33.74% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 33.74%, while the annual FY2025 figure was $1.4 billion, 42.09% up from the prior year.
  • Assets Average reached $1.4 billion in Q4 2025 per ACAD's latest filing, up from $1.3 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.4 billion in Q4 2025 and bottomed at $595.2 million in Q4 2022.
  • Average Assets Average over 5 years is $840.0 million, with a median of $730.4 million recorded in 2021.
  • Peak YoY movement for Assets Average: fell 16.4% in 2022, then skyrocketed 56.69% in 2024.
  • A 5-year view of Assets Average shows it stood at $708.9 million in 2021, then dropped by 16.05% to $595.2 million in 2022, then grew by 16.06% to $690.7 million in 2023, then surged by 56.69% to $1.1 billion in 2024, then surged by 33.74% to $1.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $1.4 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.2 billion in Q2 2025.